gms | German Medical Science

57th Annual Meeting of the German Society of Neurosurgery
Joint Meeting with the Japanese Neurosurgical Society

German Society of Neurosurgery (DGNC)

11 - 14 May, Essen

[18F]-Galacto-RGD-PET and expression of alpha v beta 3 integrin in patients with malignant glioma

[18F]-Galacto-RGD-PET und Expression von alpha v beta 3 Integrin bei Patienten mit malignen Gliomen

Meeting Abstract

  • corresponding author O. Schnell - Neurochirurgische Klinik, Klinikum der Universität München - Großhadern
  • A.J. Beer - Nuklearmedizinische Klinik, Klinikum rechts der Isar, TU München
  • B. Krebs - Zentrum für Neuropathologie und Prionforschung, LMU München
  • C. Goetz - Neurochirurgische Klinik, Klinikum der Universität München - Großhadern
  • M. Schwaiger - Nuklearmedizinische Klinik, Klinikum rechts der Isar, TU München
  • J.C. Tonn - Neurochirurgische Klinik, Klinikum der Universität München - Großhadern

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 57. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie. Essen, 11.-14.05.2006. Düsseldorf, Köln: German Medical Science; 2006. DocFR.08.05

The electronic version of this article is the complete one and can be found online at:

Published: May 8, 2006

© 2006 Schnell et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Objective: One of the key players of angiogenesis in malignant glioma is integrin αvβ3. Here we show for the first time the noninvasive imaging of αvβ3-expression in patients with malignant glioma with positron emission tomography (PET) using [18F]Galacto-RGD, a 18F-labeled glycosylated αvβ3-antagonist.

Methods: Patients with glioblastoma (n=8) and adeno-carcinoma metastasis (n=1) each >2.0 cm were scanned in an Ecat-Exact-PET after intravenous injection of 150-200 MBq [18F]Galacto-RGD at 40-60 minutes p.i.. Cranial MRI scans were fused with the [18F]Galacto-RGD-PET images, using the iPlan software (Brainlab). Patients were operated using image guided surgery. Tumor biopsies taken from areas of high and low tracer uptake in the [18F]Galacto-RGD-PET were snap frozen and immunohistochemically stained for αvβ3-expression (antibody LM 609).

Results: In normal brain tissue no significant tracer accumulation was visible (mean SUV 0.09±0.04) indicating that [18F]Galacto-RGD does not cross the intact blood-brain barrier. In tumors, tracer accumulation was heterogeneous and restricted to the periphery of the tumor with no activity in the necrotic center of the lesion. SUVs ranged from 0.8 to 2.8, (mean 1.8±0.6). The mean tumor/blood and tumor/brain ratio was 1.6±0.4 and 33.6±31, respectively. Immunhistochemical staining of cryosections confirmed αvβ3-expression in the tumor periphery with predominant staining of tumor microvessels, while tumor cells showed weaker and more diffuse staining.

Conclusions: Molecular imaging with [18F]Galacto-RGD and PET is helpful in patients with malignant glioma and may assist in the planning and monitoring of new anti-angiogenic therapies targeting the αvβ3 integrin receptor.